Skip to main content

Table 5 Comparative analysis of AITL patients based on the remission status at the time of allo-HCT

From: Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

  CR1 (N = 33) CR > 1 (N = 75) PR (N = 90) Refractory (N = 38)
Outcomes N Prob (95% CI) N Prob (95% CI) N Prob (95% CI) N Prob (95% CI)
NRM 33   75   90   38  
1-year   6 (1–17)%   20 (12–30)%   20 (13–29)%   24 (12–38)%
2-year   13 (4–26)%   29 (19–40)%   25 (17–35)%   30 (16–45)%
3-year   17 (6–32)%   31 (21–43)%   25 (17–35)%   30 (16–45)%
4-year   17 (6–32)%   36 (25–49)%   33 (22–44)%   30 (16–45)%
Progression/ relapse 33   75   90   38  
1-year   15 (5–29)%   13 (7–22)%   14 (7–21)%   29 (16–44)%
2-year   25 (12–41)%   16 (9–26)%   19 (11–28)%   29 (16–44)%
3-year   25 (12–41)%   18 (10–28)%   19 (11–28)%   32 (18–48)%
4-year   25 (12–41)%   18 (10–28)%   21 (12–30)%   32 (18–48)%
PFS 33   75   90   38  
1-year   79 (63–91)%   67 (56–77)%   66 (56–76)%   47 (32–63)%
2-year   62 (45–78)%   54 (43–66)%   56 (45–66)%   41 (26–57)%
3-year   58 (41–75)%   50 (38–62)%   56 (45–66)%   38 (23–54)%
4-year   58 (41–75)%   45 (33–58)%   47 (36–58)%   38 (23–54)%
Overall survival 33   75   90   38  
1-year   88 (75–97)%   73 (63–83)%   71 (61–80)%   63 (47–78)%
2-year   78 (62–90)%   62 (51–73)%   59 (48–69)%   52 (36–67)%
3-year   70 (52–85)%   58 (46–70)%   57 (47–68)%   52 (36–67)%
4-year   70 (52–85)%   54 (41–66)%   50 (39–62)%   52 (36–67)%
  1. CR complete response, PR partial response, Prob probability, CI confidence interval, N number, NRM non-relapse mortality, PFS progression-free survival